 Translocation, Genetic
"Translocation, Genetic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.
| Descriptor ID |
D014178
|
| MeSH Number(s) |
C23.550.210.870 G05.355.600.860 G05.365.590.175.870
|
| Concept/Terms |
Translocation, Genetic- Translocation, Genetic
- Genetic Translocation
- Genetic Translocations
- Translocations, Genetic
- Chromosomal Translocation
- Chromosomal Translocations
- Translocations, Chromosomal
- Translocation, Chromosomal
|
Below are MeSH descriptors whose meaning is more general than "Translocation, Genetic".
Below are MeSH descriptors whose meaning is more specific than "Translocation, Genetic".
This graph shows the total number of publications written about "Translocation, Genetic" by people in UAMS Profiles by year, and whether "Translocation, Genetic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 2 | 3 | 5 | | 2023 | 0 | 1 | 1 | | 2022 | 0 | 3 | 3 | | 2021 | 2 | 1 | 3 | | 2020 | 2 | 3 | 5 | | 2019 | 3 | 3 | 6 | | 2018 | 2 | 1 | 3 | | 2017 | 2 | 4 | 6 | | 2016 | 2 | 2 | 4 | | 2015 | 1 | 1 | 2 | | 2014 | 6 | 3 | 9 | | 2013 | 5 | 6 | 11 | | 2012 | 2 | 4 | 6 | | 2011 | 3 | 1 | 4 | | 2010 | 4 | 2 | 6 | | 2009 | 0 | 1 | 1 | | 2008 | 1 | 3 | 4 | | 2007 | 2 | 6 | 8 | | 2006 | 3 | 3 | 6 | | 2005 | 5 | 5 | 10 | | 2004 | 3 | 3 | 6 | | 2003 | 7 | 2 | 9 | | 2002 | 4 | 1 | 5 | | 2001 | 1 | 1 | 2 | | 1998 | 3 | 0 | 3 | | 1997 | 1 | 1 | 2 | | 1996 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Translocation, Genetic" by people in Profiles over the past ten years.
-
Cirrincione AM, Poos AM, Ziccheddu B, Kaddoura M, B?rtsch MA, Maclachlan K, Chojnacka M, Diamond B, John L, Reichert P, Huhn S, Blaney P, Gagler D, Rippe K, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Usmani S, Landgren O, Raab MS, Weinhold N, Maura F. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma. Blood. 2024 08 15; 144(7):771-783.
-
Binz RL, Pathak R. G-Banding and Molecular Cytogenetics Detect Novel Translocations and Cryptic Aberrations in Human Immortal Endothelial Cells. Int J Mol Sci. 2024 Jul 20; 25(14).
-
Sobh A, Encinas E, Patel A, Surapaneni G, Bonilla E, Kaestner C, Poullard J, Clerio M, Vasan K, Freeman T, Lv D, Dup?r?-Richer D, Riva A, Barwick BG, Zhou D, Boise LH, Mitsiades CS, Kim B, Bennett RL, Chandel NS, Licht JD. NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome. Blood. 2024 07 18; 144(3):283-295.
-
Maura F, Coffey DG, Stein CK, Braggio E, Ziccheddu B, Sharik ME, Du MT, Tafoya Alvarado Y, Shi CX, Zhu YX, Meermeier EW, Morgan GJ, Landgren O, Bergsagel PL, Chesi M. The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans. Nat Commun. 2024 May 07; 15(1):3844.
-
Chojnacka M, Diamond B, Ziccheddu B, Rustad E, Maclachlan K, Papadimitriou M, Boyle EM, Blaney P, Usmani S, Morgan G, Landgren O, Maura F. Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma. Clin Cancer Res. 2024 02 01; 30(3):575-585.
-
Malaga ML, Carrillo LF. FISH-negative, karyotype-negative acute promyelocytic leukemia. Blood. 2023 10 12; 142(15):1328.
-
Liu E, Becker N, Sudha P, Dong C, Liu Y, Keats J, Morgan G, Walker BA. Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway. Blood Cancer J. 2023 01 20; 13(1):16.
-
Meagher M, Myasnikov A, Enemark EJ. Two Distinct Modes of DNA Binding by an MCM Helicase Enable DNA Translocation. Int J Mol Sci. 2022 Nov 24; 23(23).
-
Rico D, Kent D, Karataraki N, Mikulasova A, Berlinguer-Palmini R, Walker BA, Javierre BM, Russell LJ, Brackley CA. High-resolution simulations of chromatin folding at genomic rearrangements in malignant B cells provide mechanistic insights into proto-oncogene deregulation. Genome Res. 2022 Jul 27; 32(7):1355-1366.
-
Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, Hsu CC, Wang L, Fitzsimons E, Salminen O, Blaney P, Czader M, Williams J, Abu Zaid MI, Ansari-Pour N, Yong KL, van Rhee F, Pierceall WE, Morgan GJ, Flynt E, Gooding S, Abonour R, Ramasamy K, Thakurta A, Walker BA. Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clin Cancer Res. 2022 07 01; 28(13):2854-2864.
-
Mikulasova A, Kent D, Trevisan-Herraz M, Karataraki N, Fung KTM, Ashby C, Cieslak A, Yaccoby S, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Morgan GJ, Asnafi V, Spicuglia S, Brackley CA, Corcoran AE, Hambleton S, Walker BA, Rico D, Russell LJ. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome Res. 2022 07; 32(7):1343-1354.
-
Ahn JH, Davis ES, Daugird TA, Zhao S, Quiroga IY, Uryu H, Li J, Storey AJ, Tsai YH, Keeley DP, Mackintosh SG, Edmondson RD, Byrum SD, Cai L, Tackett AJ, Zheng D, Legant WR, Phanstiel DH, Wang GG. Phase separation drives aberrant chromatin looping and cancer development. Nature. 2021 07; 595(7868):591-595.
-
Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, Johnson SK, Wardell CP, Thanendrarajan S, Zangari M, Facon T, Dumontet C, Barlogie B, Arbini A, Rustad EH, Maura F, Landgren O, Zhan F, van Rhee F, Schinke C, Davies FE, Morgan GJ, Walker BA. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun. 2021 01 12; 12(1):293.
-
Kaufman JL, Dimopoulos MA, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Sutherland HJ, Magen H, Iida S, Kim JS, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Trivedi S, Casneuf T, Krevvata M, Ukropec J, Kobos R, Avet-Loiseau H, Usmani SZ, San-Miguel J. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer J. 2020 11 03; 10(11):111.
-
Hoang PH, Cornish AJ, Sherborne AL, Chubb D, Kimber S, Jackson G, Morgan GJ, Cook G, Kinnersley B, Kaiser M, Houlston RS. An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. Blood Cancer J. 2020 10 14; 10(10):101.
-
Choudhury SR, Ashby C, Tytarenko R, Bauer M, Wang Y, Deshpande S, Den J, Schinke C, Zangari M, Thanendrarajan S, Davies FE, van Rhee F, Morgan GJ, Walker BA. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol. 2020 08 06; 13(1):108.
-
Schinke C, Boyle EM, Ashby C, Wang Y, Lyzogubov V, Wardell C, Qu P, Hoering A, Deshpande S, Ryan K, Thanendrarajan S, Mohan M, Yarlagadda N, Khan M, Choudhury SR, Zangari M, van Rhee F, Davies F, Barlogie B, Morgan G, Walker BA. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer J. 2020 06 19; 10(6):70.
-
Jagosky MH, Usmani SZ. Extramedullary Disease in Multiple Myeloma. Curr Hematol Malig Rep. 2020 04; 15(2):62-71.
-
Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res. 2019 11 15; 25(22):6781-6787.
-
Sawyer JR, Tian E, Walker BA, Wardell C, Lukacs JL, Sammartino G, Bailey C, Schinke CD, Thanendrarajan S, Davies FE, Morgan GJ, Barlogie B, Zangari M, van Rhee F. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer J. 2019 08 09; 9(8):62.
-
Srinivasan G, Williamson EA, Kong K, Jaiswal AS, Huang G, Kim HS, Sch?rer O, Zhao W, Burma S, Sung P, Hromas R. MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers. Proc Natl Acad Sci U S A. 2019 08 27; 116(35):17438-17443.
-
Binz RL, Tian E, Sadhukhan R, Zhou D, Hauer-Jensen M, Pathak R. Identification of novel breakpoints for locus- and region-specific translocations in 293 cells by molecular cytogenetics before and after irradiation. Sci Rep. 2019 07 22; 9(1):10554.
-
Meagher M, Epling LB, Enemark EJ. DNA translocation mechanism of the MCM complex and implications for replication initiation. Nat Commun. 2019 07 15; 10(1):3117.
-
Mikulasova A, Ashby C, Tytarenko RG, Qu P, Rosenthal A, Dent JA, Ryan KR, Bauer MA, Wardell CP, Hoering A, Mavrommatis K, Trotter M, Deshpande S, Yaccoby S, Tian E, Keats J, Auclair D, Jackson GH, Davies FE, Thakurta A, Morgan GJ, Walker BA. Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma. Haematologica. 2020 04; 105(4):1055-1066.
-
Singh ZN, Richards S, El Chaer F, Duong VH, Gudipati MA, Waters EO, Koon S, Webley M, Pitel B, Hoppman NL, Baer MR, Zou YS. Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm. Leuk Lymphoma. 2019 05; 60(5):1304-1307.
-
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597.
-
Sk?lov? A, Stenman G, Simpson RHW, Hellquist H, Slouka D, Svoboda T, Bishop JA, Hunt JL, Nibu KI, Rinaldo A, Vander Poorten V, Devaney KO, Steiner P, Ferlito A. The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas. Am J Surg Pathol. 2018 02; 42(2):e11-e27.
-
Walker BA. Whole Exome Sequencing in Multiple Myeloma to Identify Somatic Single Nucleotide Variants and Key Translocations Involving Immunoglobulin Loci and MYC. Methods Mol Biol. 2018; 1792:71-95.
-
Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017 08 24; 17(9):543-556.
-
Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, Begum DB, Proszek PZ, Jones JR, Pawlyn C, Savola S, Jenner MW, Drayson MT, Owen RG, Houlston RS, Cairns DA, Gregory WM, Cook G, Davies FE, Jackson GH, Morgan GJ, Kaiser MF. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018 01; 32(1):102-110.
-
Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017 09; 102(9):1617-1625.
-
Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget. 2017 Apr 25; 8(17):27854-27867.
-
Zou YS, Hoppman NL, Singh ZN, Sawhney S, Kotiah SD, Baer MR. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate. Cancer Genet. 2017 04; 212-213:38-44.
-
Pathak R, Koturbash I, Hauer-Jensen M. Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization (mFISH) and Spectral Karyotyping (SKY) in Irradiated Mice. J Vis Exp. 2017 01 11; (119).
-
Qiang YW, Ye S, Chen Y, Buros AF, Edmonson R, van Rhee F, Barlogie B, Epstein J, Morgan GJ, Davies FE. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood. 2016 12 22; 128(25):2919-2930.
-
Wren D, Walker BA, Br?ggemann M, Catherwood MA, Pott C, Stamatopoulos K, Langerak AW, Gonzalez D. Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing. Haematologica. 2017 02; 102(2):e57-e60.
-
V?tsveen TK, B?rset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T. VOLIN and KJON-Two novel hyperdiploid myeloma cell lines. Genes Chromosomes Cancer. 2016 11; 55(11):890-901.
-
Jurczyszyn A, Olszewska-Szopa M, Hungria V, Crusoe E, Pika T, Delforge M, Leleu X, Rasche L, Nooka AK, Druzd-Sitek A, Walewski J, Davila J, Caers J, Maisnar V, Gertz M, Gentile M, Fantl D, Mele G, Vesole DH, Yee AJ, Shustik C, Lentzsch S, Zweegman S, Gozzetti A, Skotnicki AB, Castillo JJ. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 09; 57(9):2071-6.
-
Hromas R, Williamson E, Lee SH, Nickoloff J. PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER. Trans Am Clin Climatol Assoc. 2016; 127:176-195.
-
Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016 Mar; 101(3):e116-9.
-
Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood. 2015 Jun 11; 125(24):3756-9.
-
Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015 Apr 23; 6:6997.
-
Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015 Jan 29; 125(5):831-40.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|